Dual-listed AFT Pharmaceuticals has signed a deal to make and sell the intravenous form of its proprietary pain relief medicine, Maxigesic IV, in China, the largest pharma market in Asia and second-largest in the world.
The deal, the ninth for Maxigesic IV out of the top 10 pharma markets worldwide,
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
